These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38111295)

  • 1. Venous Thromboembolism Prophylaxis in Low Body Weight Critically Ill Patients.
    Knox H; Edwin SB; Giuliano C; Paxton RA
    J Intensive Care Med; 2024 May; 39(5):493-498. PubMed ID: 38111295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
    Marciniak CM; Kaplan J; Welty L; Chen D
    PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery.
    Amaral FC; Baptista-Silva JC; Nakano LC; Flumignan RL
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013683. PubMed ID: 36413425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients.
    DeBiase C; Giuliano CA; Doshi M; Ganoff M; Alexander Paxton R
    Pharmacotherapy; 2021 May; 41(5):424-429. PubMed ID: 33641194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically significant venous thromboembolic complications in burn patients receiving unfractionated heparin or enoxaparin as prophylaxis.
    Bushwitz J; LeClaire A; He J; Mozingo D
    J Burn Care Res; 2011; 32(6):578-82. PubMed ID: 21841495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
    Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
    Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
    Taylor A; Huang E; Waller J; White C; Martinez-Quinones P; Robinson T
    Pharmacotherapy; 2021 Jun; 41(6):508-514. PubMed ID: 33864688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice Patterns of Venous Thromboembolism Prophylaxis in Underweight, Critically Ill Patients with Neurologic Injury.
    Betthauser K; Pope H; Gowan M; Human T
    Neurocrit Care; 2017 Aug; 27(1):96-102. PubMed ID: 28097621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Experience With Pharmacological Venous Thromboembolism Prophylaxis in the Underweight and Critically Ill.
    Carter C; Bushwitz J; Gowan M; Pope H; Human T; Gibson G; Owen E; Hampton N; Whitman C
    Ann Pharmacother; 2016 Oct; 50(10):832-9. PubMed ID: 27371544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient.
    Reynolds PM; Van Matre ET; Wright GC; McQueen RB; Burnham EL; Ho PJM; Moss M; Vandivier RW; Kiser TH;
    Pharmacotherapy; 2019 Mar; 39(3):232-241. PubMed ID: 30592541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
    Walker CK; Sandmann EA; Horyna TJ; Gales MA
    Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
    Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
    Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
    Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study.
    Aljuhani O; Al Sulaiman K; Hafiz A; Eljaaly K; Alharbi A; Algarni R; Al Homaid S; Kahtani K; Alsulaiman T; Vishwakarma R; Al Ghamdi G; Alalawi M; Korayem GB
    Saudi Pharm J; 2022 Apr; 30(4):398-406. PubMed ID: 35136364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery.
    Wilsey HA; Pandya K; Beavers C; Xiaoshu L; Ather A
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):589-595. PubMed ID: 31203501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis.
    Samuel S; Li W; Dunn K; Cortes J; Nguyen T; Moussa D; Kumar A; Dao T; Beeson J; Choi HA; McCullough LD
    J Thromb Thrombolysis; 2023 May; 55(4):617-625. PubMed ID: 37029256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
    Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
    J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.